Understanding how bacteria respond to a new antimicrobial called AGXX
Official title: Elucidating bacterial responses to the novel antimicrobial AGXX
Funded at Illinois State University · NIH-10877000 · Data updated 2026-11-12
This study is looking at a new treatment called AGXX that might help fight tough infections caused by bacteria like Pseudomonas aeruginosa, which can be a problem for people with cystic fibrosis and burn injuries, to see if it can be a better option when antibiotics don’t work.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illinois State University NIH-funded |
| Lab location | 1 site (Normal, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $74,000 |
| NIH project number | 5R03AI174033-02 |
| Project ID | NIH-10877000 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cystic fibrosis or burn wounds who are at risk of infections from Pseudomonas aeruginosa.
✕Less likely to help
Patients with infections caused by bacteria other than Pseudomonas aeruginosa may not benefit from this research.
What this research studies
This research investigates the effectiveness of a novel antimicrobial compound, AGXX, against drug-resistant bacteria, particularly Pseudomonas aeruginosa, which is a common infection in cystic fibrosis patients and burn victims. The study focuses on how AGXX, which contains silver and ruthenium, kills bacteria by generating reactive oxygen species. Researchers will analyze the bacterial responses to AGXX exposure to determine its potential as a treatment option. The goal is to find alternative strategies to combat antibiotic resistance and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Previous research has shown promise in using silver-containing compounds for treating bacterial infections, indicating potential success for this novel approach.
Where this research is happening
-
Illinois State University
Normal, United States Active
Researchers
- Principal investigator: Dahl, Jan-Ulrik — Illinois State University
- Study coordinator: Dahl, Jan-Ulrik
Related research
Other NIH-funded projects on the same topics.
-
Bacterial stress responses and a potential new antimicrobial target
A bacteria-focused project explores how polyphosphate helps bacteria survive stress and how a drug already approved for humans could make bacteria more vulnerable to antibiotics.
-
Understanding how extraintestinal E. coli defends itself against reactive oxygen and chlorine
Researchers are studying how extraintestinal E. coli survive and thrive when attacked by the body's defense systems to help prevent and treat infections.
-
Genetic repair of muscle problems in Duchenne muscular dystrophy (DMD)
Aims to improve muscle and organ function in people with Duchenne muscular dystrophy by testing genetic repair approaches and smooth muscle therapies.
-
Rapid, precise at‑home friendly diagnostic test using special antibodies and tiny light-boosting particles
A new point‑of‑care test uses specially arranged antibodies and enhanced particles to detect multiple disease markers quickly and accurately.
-
Improving antibody-gold nanoparticle interactions for better diagnostics
This study is working on making better tools for medical tests by improving how antibodies are attached to tiny gold particles, which could help make tests more accurate for diagnosing different health conditions.
-
Understanding how cholera bacteria attach and cause infection
This study is looking at how the bacteria that cause cholera stick to surfaces and form protective layers, focusing on a special structure they use to do this, which could help us find new ways to prevent cholera infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.